GIBSON DUNN

Gibson Dunn Represented Arrowhead Pharmaceuticals on Concurrent Public Offerings of Convertible Notes, Common Stock, and Pre-Funded Warrants and Related Capped Call Transactions

Firm News | January 12, 2026

Gibson Dunn represented Arrowhead Pharmaceuticals, Inc. on concurrent public offerings of convertible notes, common stock, and pre-funded warrants to purchase common stock for aggregate gross proceeds of $930 million to Arrowhead and capped call transactions relating to the convertible notes. J.P. Morgan Securities and Jefferies acted as joint book-running managers for the notes offering and for the equity offering. BofA Securities, Piper Sandler, and RBC Capital Markets acted as joint bookrunners for both offerings. The Gibson Dunn capital markets team included partners Ryan Murr and Stewart McDowell and associates Lauren Navarro and Chad Kang. Partner Darius Mehraban and of counsel Adam Lapidus advised on derivatives matters. Partner Jin Hee Kim and associate Paul Rafla advised on finance matters. Partner Pamela Lawrence Endreny and associates Ryan Rott and Eytan de Gunzburg advised on tax matters.

Related People

Ryan A. Murr

Stewart McDowell

Lauren Navarro

Chad Kang

Darius Mehraban

Adam Lapidus

Jin Hee Kim

Paul Rafla

Pamela Lawrence Endreny

Ryan Rott

Related Capabilities

Capital Markets

Life Sciences

Derivatives

Finance

Tax

© 2026 Gibson, Dunn & Crutcher LLP. All rights reserved. For contact and other information, please visit us at www.gibsondunn.com. | **www.gibsondunn.com**